 |
114 Diseases |  |
361 Trials |
|
361 Trials |  |
7200 News |  |
| «12...1718192021222324252627...100101» |
- | letrozole / Generic mfg., tamoxifen / Generic mfg.
Trial completion date, Trial primary completion date: TALES: Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial (clinicaltrials.gov) - May 3, 2023
P3, N=144, Recruiting, Sponsor: University of California, San Francisco
Trial completion date: Jan 2023 --> Jan 2024 | Trial primary completion date: Jan 2023 --> Jan 2024
- | letrozole / Generic mfg.
New trial, Monotherapy: Monotherapy With Letrozole in Tubal Pregnancy (clinicaltrials.gov) - May 3, 2023
P=N/A, N=22, Active, not recruiting, Sponsor: Jagiellonian University
- | letrozole / Generic mfg.
New trial: Letrozole add-on in the Treatment of Cesarean Scar Pregnancy (clinicaltrials.gov) - May 3, 2023
P=N/A, N=28, Active, not recruiting, Sponsor: Jagiellonian University
- | letrozole / Generic mfg.
Preclinical, Journal: 1,25-Dihydroxyvitamin D inhibits hepatic diacyglycerol accumulation and ameliorates metabolic dysfunction in polycystic ovary syndrome rat models. (Pubmed Central) - May 1, 2023
Trial completion date: Jan 2023 --> Jan 2024 | Trial primary completion date: Jan 2023 --> Jan 2024 Twenty-four Sprague-Dawley rats were randomly divided into four groups: control group (CON, 2
- |||| letrozole / Generic mfg., Kisqali (ribociclib) / Novartis
Clinical: The results of @GOG 3026 presented at #SGO2023. #Ribociclib Plus #Letrozole Has Activity in Recurrent Low-Grade Serous Ovarian Cancer. From @OncLive. @kisqali_us #clinicaltrial #ovariancancer (Twitter) - Apr 30, 2023
- ||| Prolia (denosumab) / Amgen, Daiichi Sankyo, Edirol (eldecalcitol) / Roche, Taisho, Recalbon (minodronic acid) / Ono Pharma
Retrospective data, Journal, Adverse events: Examination of Risk Factors and Expression Patterns of Atypical Femoral Fractures Using the Japanese Adverse Drug Event Report Database: A Retrospective Pharmacovigilance Study. (Pubmed Central) - Apr 28, 2023
Analysis using a Weibull distribution showed wear-out failure-type AFF onset for BPs and denosumab, and both osteoporosis and cancer patients with long-term administration of these drugs showed a tendency to have an increased risk of onset. AFF developed earlier in osteoporosis patients with long-term administration of BPs and denosumab than in cancer patients.
- || letrozole / Generic mfg.
Just back from the gym Liz. Also, I cycle everywhere so that tops me op. At least that’s my thinking. Also hoping it minimises the shocking effects letrozole has on my joints. (Twitter) - Apr 28, 2023
- | Ibrance (palbociclib) / Pfizer, Apristor (onapristone XR) / Context Therap
Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date, Circulating tumor DNA, Metastases: A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer (clinicaltrials.gov) - Apr 28, 2023
P1b, N=0, Withdrawn, Sponsor: Memorial Sloan Kettering Cancer Center
AFF developed earlier in osteoporosis patients with long-term administration of BPs and denosumab than in cancer patients. N=28 --> 0 | Trial completion date: Sep 2023 --> Apr 2023 | Recruiting --> Withdrawn | Trial primary completion date: Sep 2023 --> Apr 2023
- letrozole / Generic mfg., fulvestrant / Generic mfg.
The real-world modeling of benefits demonstrated in major clinical trials on 2 HR+/HER2? metastatic breast cancer treatment with CDK4/6 inhibitor in the US: PALOMA-2 and MONALEESA-3. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4292;
N=28 --> 0 | Trial completion date: Sep 2023 --> Apr 2023 | Recruiting --> Withdrawn | Trial primary completion date: Sep 2023 --> Apr 2023 Consistent with what was reported in major clinical trials: PALOMA-2 and MONALEESA-3, receiving CDK4/6 inhibitor plus endocrine therapy (Letrozole or Fulvestrant) was associated with improved progression free survival compared with patients treated with ET alone in this
- Ibrance (palbociclib) / Pfizer
Treatment patterns and clinical outcomes following endocrine resistance among with HER2-low metastatic breast cancer: Retrospective observational study. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4291;
Following ET resistance, durability of response with subsequent CT was short and similar irrespective of number of prior lines of ET based regimens. This preliminary chart review study highlights the unmet need for a more effective therapeutic alternative to CT after ET for HR+/HER2-low mBC patients.
- Kisqali (ribociclib) / Novartis
Feasibility of treatment with another CDK4/6 inhibitor after severe ribociclib liver toxicity. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4289;
Ribociclib liver toxicity occurs mainly during the first 6 months of treatment and takes several months to recover. >
- Kisqali (ribociclib) / Novartis
First line combination of ribociclib and letrozole in patients (pts) with metastatic breast cancer (MBC): Focus on hepatic toxicity in the context of a real () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4288;
> Hermione
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma
Preliminary analysis of pyrotinib and dalpiciclib-based therapy in HER2-positive advanced breast cancer (ABC). () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4254;
P2
In HR-/HER2+ ABC, we preliminarily observed that the addition of chemotherapy could improve effectiveness of P and D, but also increase toxicities. Due to the limited sample, the findings need further confirmation.
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
Neoadjuvant pyrotinib plus trastuzumab, dalpiciclib, and letrozole for triple-positive breast cancer: A pilot trial. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4211;
P2
The results warranted further validation. Clinical trial information: NCT05228951.
- Symptom burden of patients with breast cancer on adjuvant hormone therapy: A preliminary report. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4151;
P=N/A
Based on the BCPT instrument subscales, musculoskeletal symptoms tend to be the most intrusive, with the highest mean score. Symptom burden was inversely related to higher self-efficacy represented by LORIG scores.
- letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Longitudinal trends in serum calcium, parathormone and bone mineral density in breast cancer survivors on aromatase inhibitor therapy: A single institutional cohort study. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4146;
No significant increase in PTH levels occurred during AI therapy and majority of patients with clinically significant PTH elevation also had CKD, which may have contributed also to elevation of PTH level and low urinary calcium excretion. >
- letrozole / Generic mfg., anastrozole / Generic mfg., tamoxifen / Generic mfg.
Therapy decision-making after pre-operative endocrine therapy in HR+ HER2- early breast cancer. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4136;
Mature data of long-term pts outcome are awaited. >
- letrozole / Generic mfg., tamoxifen / Generic mfg.
The effect of exercise on physical function and medication adherence in women receiving endocrine therapy for breast cancer: The Breast Cancer Endocrine Therapy Fitness (BE-FIT) randomized controlled trial. (On Demand | Hall A; Poster Bd # 437) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3664;
P=N/A
The potential impact of the intervention on long-term medication adherence will be explored up to one year and with covariates. Based on improvement in PF, future trials to establish effectiveness and inform implementation are warranted.
- Ibrance (palbociclib) / Pfizer
Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR[+])/human epidermal growth factor receptor 2-negative (HER2[-]) advanced breast cancer (ABC): PALMIRA trial. (Live Stream | Hall B1) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3344;
P2
Planned biomarker analysis may help identify which pts are more likely to benefit from this therapeutic approach. Clinical trial information: NCT03809988.
- Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis
Ribociclib (RIB) vs. palbociclib (PAL) in patients (pts) with hormone receptor-positive/HER2-negative/HER2-enriched (HR+/HER2-/HER2-E) advanced breast cancer (ABC): A head-to-head phase III study (On Demand | Hall A; Poster Bd # 339a) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3317;
P3
As per recent protocol amendment, BL cohort pts will be treated with paclitaxel plus tislelizumab, an anti PD-1 monoclonal antibody, pts may be offered to try RIB + ET first, and will remain eligible for paclitaxel + tislelizumab upon progression...HARMONIA will recruit in Spain (55 sites), Portugal (5), and US (35) within SOLTI & AFT network. Clinical trial information: NCT05207709.
- Piqray (alpelisib) / Novartis
Alpelisib + endocrine therapy in patients with PIK3CA-mutated, hormone receptor (On Demand | Hall A; Poster Bd # 299) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3270;
P2
AEs associated with ALP were well defined and manageable, with no new safety signals observed in any cohort. Clinical trial information: NCT03056755.
- Kisqali (ribociclib) / Novartis
Outcomes with first-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs physician (On Demand | Hall A; Poster Bd # 284) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3255;
P2
Pre/perimenopausal pts (aged 18-59 y) with HR+/HER2? ABC and no prior systemic therapy for ABC were randomized 1:1 to either RIB with letrozole/anastrozole + goserelin or investigator
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma
PLEASURABLE: Results and biomarkers analysis from the phase II study of dalpiciclib combined with pyrotinib and endocrine therapy (ET) in women with dual-receptor positive (ER+/HER2+) metastatic breast cancer (MBC). (On Demand | Hall A; Poster Bd # 267) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3238;
P1/2
ABC and no prior systemic therapy for ABC were randomized 1:1 to either RIB with letrozole/anastrozole + goserelin or investigator ER+/HER2+ MBC Pts eligible for first- or second-line treatment were enrolled to receive dalpiciclib combined with pyrotinib and ET (letrozole or fulvestrant determined by physician
- Ibrance (palbociclib) / Pfizer
A phase II trial of palbociclib combined to letrozole after progression on second-line chemotherapy for women with ER/PR-positive high-grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer: LACOG 1018. (On Demand | S100bc; Poster Bd # 209) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2278;
P2
These results warrant further investigation of palbociclib plus letrozole in high-grade ovarian cancer. Clinical trial information: NCT03936270.
- AFT-50 EndoMAP: A phase IB/II multi-cohort study of targeted agents for patients with recurrent or persistent endometrial cancer. (On Demand | Hall A; Poster Bd # 318a) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2274;
P1/2
In cohort A, pts may be eligible for one of the following doublets: Atezo+ipatasertib (PIK3CA/PTEN/AKT1-altered cancers), Atezo+talazoparib (tumors with genomic loss of heterozygosity (LOH) ?16%), Atezo+Trastuzumab emtansine (ERBB2/HER2 mutated and/or amplified tumors), Atezo+Tiragolumab (MSI-H and/or TMB>10 mut/MB), and Atezo+bevacizumab (biomarker unmatched)...Pts in cohort B, will be eligible for inavolisib (PIK3CA/PTEN/AKT1-altered cancers) + letrozole...EndoMAP is actively enrolling at 17 sites in the US with a target of 25 sites nationwide. Clinical trial information: NCT04486352.
- PF-07220060 / Pfizer
First-in-human first-in-class phase 1/2a study of the next generation CDK4-selective inhibitor PF-07220060 in patients (pts) with advanced solid tumors, enriched for HR+ HER2- mBC who progressed on prior CDK4/6 inhibitors and endocrine therapy. (On Demand | S100bc; Poster Bd # 207) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1868;
P1/2
Clinical trial information: NCT04486352. At data cut off (Nov 1, 2022), 34 pts with advanced solid tumors received PF-07220060 in monotherapy dose escalation (Part 1A: 100
- Evolving adjuvant estrogen therapy prescribing among breast oncology workforce. (On Demand | Hall A; Poster Bd # 140) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1496;
Over the time frame analyzed, there was no significant change in number of prescription claims annually, but an overall decrease in providers. Thus, the rise in APP prescribers is not driven by an increased prescribing volume, but rather seems to reflect an evolving surgical oncology workforce.
- goserelin acetate / Generic mfg., exemestane / Generic mfg.
A randomized phase 2 non-inferiority trial of (Z)-endoxifen and exemestane + goserelin as neoadjuvant treatment for premenopausal women with ER+/HER2- breast cancer (EVANGELINE). (Available On Demand; Poster Bd # 454a) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1020;
P2
Enrolment in the PK Run-in cohort began in February 2023. Clinical trial information: NCT05607004.
- Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
ORACLE-RIPA study: A phase II, randomized, open-label, parallel-group study comparing the immune modulation effect of neoadjuvant ribociclib, palbociclib, and abemaciclib in early ER+/HER2- breast cancer. (Available On Demand; Poster Bd # 453b) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1019;
The study is currently enrolling at 3 medical centers s in Taiwan. Clinical trial information: Pending formal number assignment.
- giredestrant (GDC-9545) / Roche
lidERA Breast Cancer (BC): Phase III adjuvant study of giredestrant vs. physician (Available On Demand; Poster Bd # 445b) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1003;
P3
It is more potent in vitro and achieves higher ER occupancy in vivo than fulvestrant...Pts are randomized 1:1 to oral 30 mg daily giredestrant or PCET (tamoxifen, anastrozole, letrozole, or exemestane; per prescribing information)...2950/4100 pts have been recruited globally. Clinical trial information: NCT04961996.
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, MHU650 / Novartis, MorphoSys, adebrelimab (SHR-1316) / Jiangsu Hengrui Pharma
A prospective, phase II, neoadjuvant clinical study based on chemotherapy sensitivity in hormone receptor (Available On Demand; Poster Bd # 437) - Apr 26, 2023 - Abstract #ASCO2023ASCO_995;
P1/2
The overall treatment strategy did not improve the efficacy, but there is still a possibility that some people can get an improvement from the strategy adjustment. Precision analysis may yield the characteristics of patients who would benefit from this shift in treatment strategy.
- Influence of ovarian function supression on quality of life in breast cancer survivors during adjuvant endocrine therapy. (Available On Demand; Poster Bd # 390) - Apr 26, 2023 - Abstract #ASCO2023ASCO_948;
Therefore, interventions helping decrease the ESB in patients treated with AI+GnRH should be explored and developed to help patients adhere to and persist in AET. >*One-way ANOVA.Social well-being (SW), emotional well-being (EWB), functional well-being (FWB).
- letrozole / Generic mfg., anastrozole / Generic mfg.
Disease-free survival (DFS) as a surrogate for overall survival (OS) in patients (pts) with HR+/HER2? early breast cancer (EBC): A correlation analysis. (Available On Demand; Poster Bd # 365) - Apr 26, 2023 - Abstract #ASCO2023ASCO_923;
These results support the use of DFS as a reliable surrogate endpoint for OS in HR+/HER2? EBC trials to give an early access to innovative therapies.
- Kisqali (ribociclib) / Novartis
Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2? early breast cancer: Primary results from the phase III NATALEE trial. (Available On Demand) - Apr 26, 2023 - Abstract #ASCO2023ASCO_902;
P3
EBC, including pts with N0 disease. Clinical trial information: NCT03701334.
- |||||| camizestrant (AZD9833) / AstraZeneca
Enrollment open, Trial completion date: CAMBRIA-1: A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy (clinicaltrials.gov) - Apr 26, 2023
P3, N=4300, Recruiting, Sponsor: AstraZeneca
Clinical trial information: NCT03701334. Not yet recruiting --> Recruiting | Trial completion date: Sep 2036 --> May 2036
- ||||||| Kisqali (ribociclib) / Novartis
Trial completion: MONALEESA-2: Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer (clinicaltrials.gov) - Apr 26, 2023
P3, N=668, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting | Trial completion date: Sep 2036 --> May 2036 Active, not recruiting --> Completed
- | diacerein / Generic mfg., letrozole / Generic mfg.
Preclinical, Journal: Role of diacerein on steroidogenesis and folliculogenesis related genes in ovary of letrozole-induced PCOS mice. (Pubmed Central) - Apr 25, 2023
All these changes were reversed after the administration of DIC in PCOS mice. Diacerin administration reversed abnormalities in mice with PCOS by modulating the regulation of genes which are related to steroidogenesis and folliculogenesis.
- |||| Ibrance (palbociclib) / Pfizer
Trial completion date, Trial primary completion date: PATINA: Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (clinicaltrials.gov) - Apr 25, 2023
P3, N=496, Active, not recruiting, Sponsor: Alliance Foundation Trials, LLC.
Diacerin administration reversed abnormalities in mice with PCOS by modulating the regulation of genes which are related to steroidogenesis and folliculogenesis. Trial completion date: Mar 2026 --> Jul 2026 | Trial primary completion date: May 2023 --> Dec 2023
- |||||| lerociclib (G1T38) / Walvax, Pepper Bio
Enrollment open, Combination therapy, Metastases: Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial Cancer (clinicaltrials.gov) - Apr 25, 2023
P3, N=320, Recruiting, Sponsor: EQRx International, Inc.
Trial completion date: Mar 2026 --> Jul 2026 | Trial primary completion date: May 2023 --> Dec 2023 Not yet recruiting --> Recruiting
- | fulvestrant / Generic mfg.
Trial primary completion date: Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study (clinicaltrials.gov) - Apr 24, 2023
P2, N=124, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Trial primary completion date: Apr 2023 --> Apr 2024
- |||||||||| Kisqali (ribociclib) / Novartis
New P3 trial, Real-world evidence: ADJUVANT WIDER: Phase IIIb Study of Ribociclib + ET in Early Breast Cancer (clinicaltrials.gov) - Apr 24, 2023
P3, N=2500, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- | Biomarker, New P2 trial: Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer (clinicaltrials.gov) - Apr 24, 2023
P2, N=500, Not yet recruiting, Sponsor: University of Miami
- |||||| culmerciclib (TQB3616) / Sino Biopharm
Enrollment open: Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer (clinicaltrials.gov) - Apr 21, 2023
P3, N=1946, Recruiting, Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Trial primary completion date: Apr 2023 --> Apr 2024 Not yet recruiting --> Recruiting
- |||| Inluriyo (imlunestrant) / Eli Lilly
Trial primary completion date: EMBER-4: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer (clinicaltrials.gov) - Apr 20, 2023
P3, N=6000, Recruiting, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting Trial primary completion date: Oct 2026 --> Oct 2027
- | Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Metastases: Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer (clinicaltrials.gov) - Apr 19, 2023
P2, N=30, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial primary completion date: Oct 2026 --> Oct 2027 Trial completion date: Jun 2023 --> Dec 2023
- |||| Inluriyo (imlunestrant) / Eli Lilly
Trial primary completion date: EMBER-4: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer (clinicaltrials.gov) - Apr 18, 2023
P3, N=6000, Recruiting, Sponsor: Eli Lilly and Company
Trial completion date: Jun 2023 --> Dec 2023 Trial primary completion date: Oct 2027 --> Oct 2026
- ||| atirmociclib (PF-07220060) / Pfizer
Enrollment change, Combination therapy, Metastases: C4391001: Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (clinicaltrials.gov) - Apr 18, 2023
P1/2, N=198, Recruiting, Sponsor: Pfizer
Trial primary completion date: Oct 2027 --> Oct 2026 N=337 --> 198
- ||| Rozlytrek (entrectinib) / Roche
Enrollment change, Trial completion date, Trial primary completion date, Combination therapy: Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE) (clinicaltrials.gov) - Apr 18, 2023
P2, N=65, Recruiting, Sponsor: Jules Bordet Institute
N=337 --> 198 N=45 --> 65 | Trial completion date: Mar 2023 --> Jul 2024 | Trial primary completion date: Oct 2022 --> Apr 2024
- | Kisqali (ribociclib) / Novartis
New P2 trial, Metastases: Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer (clinicaltrials.gov) - Apr 18, 2023
P2, N=202, Not yet recruiting, Sponsor: Korea University Guro Hospital
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open, Metastases: Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor (clinicaltrials.gov) - Apr 18, 2023
P2, N=120, Recruiting, Sponsor: National University Hospital, Singapore
N=45 --> 65 | Trial completion date: Mar 2023 --> Jul 2024 | Trial primary completion date: Oct 2022 --> Apr 2024 Not yet recruiting --> Recruiting